- Home
- APM vs ADXN Comparison
APM vs ADXN Comparison
Compare APM & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APM | ADXN |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.0M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | APM | ADXN |
|---|---|---|
| Price | $0.89 | $5.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 90.8K | 4.0K |
| Earning Date | 04-29-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $5.41 |
| 52 Week High | $4.47 | $12.05 |
Technical Indicators
Market Signals| Indicator | APM | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 52.36 |
| Support Level | $0.75 | $5.57 |
| Resistance Level | $0.86 | $7.15 |
| Average True Range (ATR) | 0.14 | 0.48 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 17.97 | 80.46 |
Price Performance
Historical ComparisonAbout APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.